Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
44.42
+0.27
+(0.61%)
At close: February 21 at 5:32:18 PM GMT+1
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 13 | 13 |
| Avg. Estimate | 6.92B | 7.14B | 28.67B | 30.09B |
| Low Estimate | 6.85B | 7.09B | 28.53B | 29.8B |
| High Estimate | 6.99B | 7.19B | 28.78B | 30.73B |
| Year Ago Sales | 6.68B | 6.84B | 27.34B | 28.67B |
| Sales Growth (year/est) | 3.51% | 4.44% | 4.89% | 4.94% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| USBC.VI | -- | -- | -- | -- |
| S&P 500 | 14.59% | 7.50% | 10.82% | 14.15% |
Upgrades & Downgrades
| Maintains | Morgan Stanley: Overweight to Overweight | 1/17/2025 |
| Maintains | Oppenheimer: Outperform to Outperform | 1/17/2025 |
| Initiated | Truist Securities: Hold | 1/7/2025 |
| Maintains | Barclays: Overweight to Overweight | 1/6/2025 |
| Maintains | Oppenheimer: Outperform to Outperform | 1/3/2025 |
| Upgrade | DA Davidson: Neutral to Buy | 1/2/2025 |